FDA gains power to block shrimp imports from countries with weak safety oversight

What it does

This bill requires the FDA to negotiate food-safety agreements with foreign governments that export shrimp to the U.S., and bars shrimp imports from countries that refuse to negotiate or whose inspection systems don't match FDA standards. Starting one year after enactment, shrimp from non-compliant countries will be refused entry. The bill benefits U.S. consumers by raising safety standards for imported shrimp; it may increase compliance costs for foreign shrimp producers and exporters.

Why we flagged it

The bill's operative mechanism is a regulatory equivalency requirement: it sets a safety floor for imported shrimp by requiring foreign inspection systems to match FDA standards, backed by an import ban for non-compliant countries. This is a public-health standard-setting measure, not a trade restriction or industry carve-out.

What the text implies

• The bill grants the FDA discretion to determine what constitutes 'equivalent' inspection systems, potentially creating leverage in trade negotiations or disputes with shrimp-exporting nations.
• Foreign governments must provide copies of all laws and regulations governing shrimp inspection to the FDA; this transparency requirement may expose proprietary or sensitive regulatory information.
• The 180-day negotiation window and 1-year implementation delay create a transition period during which non-compliant shrimp may still enter the U.S., potentially delaying safety gains.
• Annual reporting requirement to Congress may create political pressure on the FDA to enforce the standard uniformly or face legislative scrutiny, affecting agency independence.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary U.S. consumers gain a concrete safety protection: shrimp imports will be subject to FDA-equivalent inspection standards, reducing foodborne illness risk from a major imported protein. The bill imposes compliance costs on foreign producers, not on consumers or domestic businesses.

Who stands to gain

• U.S. domestic shrimp producers (reduced competition from non-compliant foreign imports)
• U.S. seafood importers and distributors (those already sourcing from compliant countries gain compet

Named in the bill

FDA (Food and Drug Administration), HHS (Department of Health and Human Services), Foreign governments (shrimp-exporting countries), Section 807, Federal Food, Drug, and Cosmetic Act, Section 402, Federal Food, Drug, and Cosmetic Act, Section 415, Federal Food, Drug, and Cosmetic Act, House Committee on Energy and Commerce, Senate Committee on Health, Education, Labor, and Pensions

Where it stands

5 cosponsors: 4 Republicans, 1 Democrats.

• May 13, 2025 — Introduced · Congress.gov: “Introduced in House”
• May 13, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 2 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $75,000 in lobbying spend. A filing names 26 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Mike Ezell, the sponsor, reported $480,431 in PAC receipts in the 2026 cycle.

• Southern Shrimp Alliance — $45,000 on 1 filing
• Mondelez International, Inc. — $30,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.